Zacks Investment Research upgraded shares of Procaps Group (NASDAQ:PROC – Get Rating) from a sell rating to a hold rating in a research note published on Saturday, Zacks.com reports.
According to Zacks, “Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps Group, formerly known as Union Acquisition Corp. II, is based in BARRANQUILLA, Colombia. “
PROC opened at $8.01 on Friday. The company has a 50 day moving average of $8.06 and a two-hundred day moving average of $8.87. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 3.12. Procaps Group has a 52-week low of $5.86 and a 52-week high of $11.98.
About Procaps Group (Get Rating)
Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.
Featured Articles
- Get a free copy of the StockNews.com research report on Procaps Group (PROC)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Get a free copy of the Zacks research report on Procaps Group (PROC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Procaps Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procaps Group and related companies with MarketBeat.com's FREE daily email newsletter.